1
|
Kurtaran A, Schmoll-Hauer B, Tugendsam C. Aktuelle Diskussion zur risikoadaptierten Therapie des differenzierten Schilddrüsenkarzinoms: Ist weniger (Therapie) wirklich mehr? Wien Med Wochenschr 2019; 170:15-25. [DOI: 10.1007/s10354-019-00713-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Revised: 09/18/2019] [Accepted: 10/15/2019] [Indexed: 12/20/2022]
|
2
|
Kelkar MG, Thakur B, Derle A, Chatterjee S, Ray P, De A. Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer. Breast Cancer Res Treat 2017; 164:603-615. [PMID: 28528452 DOI: 10.1007/s10549-017-4297-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Accepted: 05/14/2017] [Indexed: 12/28/2022]
Abstract
PURPOSE Aberrant expression of human sodium iodide symporter (NIS) in breast cancer (BC) is well documented but the transcription factors (TF) regulating its aberrant expression is poorly known. We identify the presence of three p53 binding sites on the human NIS promoter sequence by conducting genome-wide TF analysis, and further investigate their regulatory role. METHODS The differences in transcription and translation were measured by real-time PCR, luciferase reporter assay, site-directed mutagenesis, in vivo optical imaging, and chromatin immunoprecipitation. The relation of NIS and p53 in clinical samples was judged by TCGA data analysis and immunohistochemistry. RESULTS Overexpression of wild-type p53 as a transgene or pharmacological activation by doxorubicin drug treatment shows significant suppression of NIS transcription in multiple BC cell types which also results in lowered NIS protein content and cellular iodide intake. NIS repression by activated p53 is further confirmed by non-invasive bioluminescence imaging in live cell and orthotropic tumor model. Abrogation of p53-binding sites by directional mutagenesis confirms reversal of transcriptional activity in wild-type p53-positive BC cells. We also observe direct binding of p53 to these sites on the human NIS promoter. Importantly, TCGA data analysis of NIS and p53 co-expression registers an inverse relationship between the two candidates. CONCLUSION Our data for the first time highlight the role of p53 as a negative regulator of functional NIS expression in BC, where the latter is a potential targeted radioiodine therapy candidate. Thus, the study provides an important insight into prospective clinical application of this approach that may significantly impact the patient with mutant versus wild-type p53 profile.
Collapse
Affiliation(s)
- Madhura G Kelkar
- Molecular Functional Imaging Lab, Tata Memorial Centre, ACTREC, Sector 22, Kharghar, Navi Mumbai, 410210, India.,Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India
| | - Bhushan Thakur
- Imaging Cell Signaling and Therapeutics Lab, Tata Memorial Centre, ACTREC, Navi Mumbai, India.,Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India
| | - Abhishek Derle
- Molecular Functional Imaging Lab, Tata Memorial Centre, ACTREC, Sector 22, Kharghar, Navi Mumbai, 410210, India
| | - Sushmita Chatterjee
- Molecular Functional Imaging Lab, Tata Memorial Centre, ACTREC, Sector 22, Kharghar, Navi Mumbai, 410210, India
| | - Pritha Ray
- Imaging Cell Signaling and Therapeutics Lab, Tata Memorial Centre, ACTREC, Navi Mumbai, India.,Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India
| | - Abhijit De
- Molecular Functional Imaging Lab, Tata Memorial Centre, ACTREC, Sector 22, Kharghar, Navi Mumbai, 410210, India. .,Homi Bhabha National Institute, Anushakti Nagar, Mumbai, India.
| |
Collapse
|
3
|
Thazhath RV, Purayil LP, Purayil AV. THYROID HORMONE PROFILE IN EARLY BREAST CANCER PATIENTS. ACTA ACUST UNITED AC 2016. [DOI: 10.18410/jebmh/2016/490] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Kahmann C, Wunderlich G, Freudenberg R, Zöphel K, Oehme L, Kotzerke J. Radioprotection of thyroid cells mediated by methimazole. Int J Radiat Biol 2010; 86:811-6. [PMID: 20608812 DOI: 10.3109/09553002.2010.488276] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE The radioprotective effect of antithyroid drugs on radioiodine treatment is a controversial issue. However, it is of clinical relevance whether antithyroid medication has to be interrupted for therapy and when antithyroid medication can be continued after radioiodine treatment. We investigated DNA damage caused by internal or external radiation using thyroid cells (sodium iodine symporter [NIS] positive). MATERIALS AND METHODS Adherent thyroid cells were irradiated following incubation with the mediators methimazole and perchlorate using either X-ray tube or Re-188-perrhenate. DNA damage was quantified by OTM (Olive's tail moment) of the alkaline comet assay. RESULTS Following external irradiation of 15 Gy OTM was 4.3 ± 4.2 compared to 0.5 ± 1.4 in controls. DNA damage was reduced by methimazole to 70%. Incubation with Re-188 showed effects depending on presence of the mediators. Non-irradiated controls had a mean OTM < 1, internal irradiation increased OTM to 25.5 ± 9.1 in cells without mediators. OTM decreased to 60% after pre-incubation with methimazole and to 15% with perchlorate. Re-188 uptake was modified by both perchlorate and, to a lesser extent, methimazole. CONCLUSIONS Methimazole was shown to have a radioprotective effect not only by its scavenger capacity but also by interaction with NIS. Perchlorate acted by competitive inhibition of NIS mediated Re-188 uptake.
Collapse
Affiliation(s)
- Cindy Kahmann
- Department of Nuclear Medicine, University Hospital, Technische Universität Dresden, Germany
| | | | | | | | | | | |
Collapse
|
5
|
Sabitha, Suneetha, Mohanty S, Rao P. Serum anti - TPO levels in benign and malignant breast tumors. Indian J Clin Biochem 2009; 24:266-8. [PMID: 23105847 DOI: 10.1007/s12291-009-0050-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Breast cancer is a hormone dependent neoplasm. Conflicting results regarding the clinical correlation between breast cancer and thyroid diseases have been reported. The objective of this study was to determine the association of anti - TPO levels in patients having complaints of a lump in breast. Serum samples and Fine needle aspiration cytology (FNAC) samples were collected from 31 female patients with a lump in breast between the age group of 20-75 years. 31 age matched normal healthy controls were also examined for the same parameters. Serum samples were analyzed for its anti - TPO levels. FNAC reports confirmed patients as having duct cell carcinoma. They had raised serum anti - TPO levels compared to controls. FNAC results of others (n=26) were reported as fibroadenoma whose anti - TPO levels were less than the controls.
Collapse
Affiliation(s)
- Sabitha
- Kamineni Institute of Medical Sciences, Sreepuram, Narketpally, Nalgonda, 508254 Andhra Pradesh India
| | | | | | | |
Collapse
|
6
|
Dülger H, Alıcı S, Algün E, Etlik Ö, Sayarlıoğlu M, Doğan E, Sayarlıoğlu H, Şekeroğlu MR. Antithyroid Antibody Levels in Patients with Breast Cancer. ELECTRONIC JOURNAL OF GENERAL MEDICINE 2004. [DOI: 10.29333/ejgm/82174] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|